川宁生物
(301301)
| 流通市值：61.96亿 | | | 总市值：223.68亿 |
| 流通股本：6.18亿 | | | 总股本：22.30亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 664,172,368.15 | 734,213,300.93 | 747,734,814.73 | 808,484,774.9 |
| 交易性金融资产 | - | - | - | 4,354.45 |
| 应收票据及应收账款 | 1,148,278,179.14 | 1,033,108,420.33 | 971,765,969.39 | 1,028,499,781.23 |
| 应收账款 | 1,148,278,179.14 | 1,033,108,420.33 | 971,765,969.39 | 1,028,499,781.23 |
| 应收款项融资 | 862,634,114.86 | 751,491,043.35 | 564,084,801.71 | 797,180,216.88 |
| 预付款项 | 116,810,176.82 | 110,957,644.01 | 490,580,029.13 | 108,203,249.76 |
| 其他应收款合计 | 907,992.74 | 283,937.07 | 860,966.96 | 1,246,915.16 |
| 存货 | 1,322,095,281.76 | 1,500,308,074.01 | 1,071,619,189.64 | 1,099,753,774.36 |
| 其他流动资产 | 76,001,514.31 | 78,733,000.91 | 175,035,245.33 | 73,108,206.24 |
| 流动资产合计 | 4,190,899,627.78 | 4,209,095,420.61 | 4,021,681,016.89 | 3,916,481,272.98 |
| 非流动资产: | | | | |
| 长期股权投资 | 181,189,999.88 | 148,458,206.29 | 146,821,327.94 | 37,102,039.87 |
| 其他权益工具投资 | 25,224,217.92 | 25,224,217.92 | 24,883,131.36 | 24,883,131.36 |
| 其他非流动金融资产 | 46,516,782.11 | 28,516,782.11 | 30,000,000 | 30,000,000 |
| 固定资产 | 4,890,524,714.83 | 4,981,358,796.37 | 5,001,762,901.7 | 5,041,928,525.73 |
| 在建工程 | 309,547,501.21 | 277,214,374.89 | 330,324,789.2 | 329,427,851.73 |
| 使用权资产 | 468,327,295.11 | 472,245,747.95 | 473,316,443.33 | 477,730,861.28 |
| 无形资产 | 236,682,275.39 | 228,912,080.88 | 233,981,581.63 | 238,961,367.43 |
| 开发支出 | - | - | 1,000,000 | 1,000,000 |
| 商誉 | 1,365,974 | 1,365,974 | 1,365,974 | 1,365,974 |
| 长期待摊费用 | 439,126.5 | 658,689.75 | 878,253.01 | 1,097,816.26 |
| 递延所得税资产 | 20,174,249.97 | 21,773,417.23 | 23,660,361.78 | 23,928,973.17 |
| 其他非流动资产 | 32,051,800.55 | 34,656,569.97 | 41,101,900.55 | 35,396,478.78 |
| 非流动资产合计 | 6,212,043,937.47 | 6,220,384,857.36 | 6,309,096,664.5 | 6,242,823,019.61 |
| 资产总计 | 10,402,943,565.25 | 10,429,480,277.97 | 10,330,777,681.39 | 10,159,304,292.59 |
| 流动负债: | | | | |
| 短期借款 | 760,482,252.22 | 560,353,307.78 | 360,139,102.22 | 210,138,694.44 |
| 交易性金融负债 | 901,170 | 0 | 226,400 | - |
| 应付票据及应付账款 | 695,586,302.01 | 710,489,881.38 | 655,307,626.43 | 663,543,228.39 |
| 其中：应付票据 | - | 0 | - | - |
| 应付账款 | 695,586,302.01 | 710,489,881.38 | 655,307,626.43 | 663,543,228.39 |
| 预收款项 | - | 0 | - | - |
| 合同负债 | 15,271,051.36 | 19,225,375.4 | 18,628,495.65 | 46,630,525.73 |
| 应付职工薪酬 | 27,592,915.43 | 29,008,471.96 | 28,848,214.88 | 27,617,787.75 |
| 应交税费 | 89,924,315.14 | 53,381,772.41 | 92,634,952.12 | 88,171,712.11 |
| 其他应付款合计 | 29,046,182.78 | 11,715,656.3 | 40,157,996.36 | 31,889,701.9 |
| 一年内到期的非流动负债 | 10,564,904.42 | 156,569,761.85 | 402,486,073.27 | 737,627,814.42 |
| 其他流动负债 | 1,743,318.7 | 203,629,074.71 | 202,635,778.06 | 5,709,046.79 |
| 流动负债合计 | 1,631,112,412.06 | 1,744,373,301.79 | 1,801,064,638.99 | 1,811,328,511.53 |
| 非流动负债: | | | | |
| 长期借款 | - | 0 | - | - |
| 租赁负债 | 448,062,665.43 | 469,731,985.1 | 464,446,911.53 | 459,840,638.01 |
| 预计负债 | 5,265,651.72 | 3,743,022.66 | 2,824,429.57 | 2,999,965.19 |
| 递延收益 | 100,055,815.74 | 103,799,153.17 | 110,920,029.46 | 98,068,040.25 |
| 递延所得税负债 | - | - | 11,721.32 | 86,231.48 |
| 非流动负债合计 | 553,384,132.89 | 577,274,160.93 | 578,203,091.88 | 560,994,874.93 |
| 负债合计 | 2,184,496,544.95 | 2,321,647,462.72 | 2,379,267,730.87 | 2,372,323,386.46 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 2,230,085,000 | 2,230,085,000 | 2,230,085,000 | 2,230,085,000 |
| 资本公积 | 3,298,859,644.84 | 3,298,263,225.6 | 3,299,672,495.23 | 3,298,671,736.44 |
| 其他综合收益 | 190,585.24 | 190,585.24 | -99,338.34 | -99,338.34 |
| 盈余公积 | 417,531,230.15 | 417,531,230.15 | 325,319,096.72 | 325,319,096.72 |
| 未分配利润 | 2,247,123,830.15 | 2,136,396,714.31 | 2,070,993,092.53 | 1,914,458,192.58 |
| 归属于母公司股东权益合计 | 8,193,790,290.38 | 8,082,466,755.3 | 7,925,970,346.14 | 7,768,434,687.4 |
| 少数股东权益 | 24,656,729.92 | 25,366,059.95 | 25,539,604.38 | 18,546,218.73 |
| 股东权益合计 | 8,218,447,020.3 | 8,107,832,815.25 | 7,951,509,950.52 | 7,786,980,906.13 |
| 负债和股东权益合计 | 10,402,943,565.25 | 10,429,480,277.97 | 10,330,777,681.39 | 10,159,304,292.59 |
| 公告日期 | 2026-04-23 | 2026-03-31 | 2025-10-28 | 2025-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |